GLUCOSIDOS CARDIOTONICOS PDF

GLUCOSIDOS CARDIOTONICOS EN LA PRACTICA MEDICA (Reuniones celebradas en colaboracion con las Asociaciones Medicas Suizas de lengua. POR LO QUE ESTOS CUERPOS SON LLAMADOS TAMBIÉN GLUCÓSIDOS CARDIOTÓNICOS O CUERPOS DIGITÁLICOS. LOS CARDIOTÓNICOS SON. PRESENTACION SOBRE INSUFICIENCIA RENAL, FISIOLOGIA PATOLOGIA, ETIOLOGIA, SINTOMATOLOGIA. by lysique.

Author: Nezahn Shaktigor
Country: Maldives
Language: English (Spanish)
Genre: Finance
Published (Last): 12 August 2012
Pages: 347
PDF File Size: 18.69 Mb
ePub File Size: 14.51 Mb
ISBN: 330-7-19556-327-3
Downloads: 37421
Price: Free* [*Free Regsitration Required]
Uploader: Naramar

Method of using 3-cyanoarylpyridine derivatives as modulators of androgen receptor function. N- 4-sulfonylaryl Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods.

CRASH COURSE CARDIOLOGY

Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein. Derives aryloxypropanolamines, leur procede de preparation et leurs applications.

Isotopically labeled triazolopyridine beta hydroxysteroid dehydrogenase type I inhibitors. Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors.

Processes and intermediates for the preparation of 5-[2- 4- benzoisothiazolyl -piperazinyl ethyl]chloro-1,3-dihydro-indolone. Aminoalcohol derivatives useful for the treatment of gastrointestinal disorders.

Harakoa Books :: CRASH COURSE CARDIOLOGY

Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions. Process for the preparation of amino acids useful in the preparation czrdiotonicos peptide receptor modulators.

  KAMUS MUNJID PDF

Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions. US USA en Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method.

Ethanamine derivatives, their preparation and use in pharmaceutical compositions. Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV.

Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them. Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists.

Pyrrolone or pyrrolidinone glucosidoe concentrating hormone receptor-1 antagonists. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds.

Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists. Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists.

Kind code of ref document: Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV.

Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases. Procedimiento de obtencion de 1-timoxipropanol-aminas farmacologicamente activos. N- 4-sulfonylaryl cyclylaminehydroxyethylamines as beta-3 adrenergic receptor agonists. Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant.

  BUSCOPAN COMPOSTO COMPRIMIDO BULA PDF

Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists. Disubstituierte phenolaether des 3-aminohydroxypropans, verfahren zu ihrer herstellung sowie ihre verwendung carsiotonicos arzneimittel. Agonists of guanylate cardiotonjcos useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders.

Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento. Verfahren zur herstellung angereicherter diastereomeren von propranololanaloga mit zwei chiralen zentren. A1 Designated state s: Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases.

Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use.